Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison

Versiani, Márcio; Ontiveros, Alfonso; Mazzotti, Guido; Ospina, Jessica Marín; Davila, Josue; Mata, Salvador; Pacheco, Andreia; Plewes, John; Tamura, Roy; Palacios, Moreno

doi:10.1097/00004850-199911000-00001

Cited by 33 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with past research, mean endpoint dose among responders in our study (429 mg/day) was over 400 mg/day, the value identified by a dose-finding trial among predominantly non-Hispanic White subjects as being associated with the greatest number of responders at the onset of sustained response [Mendels et al, 1995]. Our findings are in contrast to Marcos and Cancro's retrospective report of lower dose requirements for firstgeneration tricyclics among depressed Caribbean Hispanics [Marcos and Cancro, 1982] but in agreement with previous prospective medication trials among mixed Hispanic populations [Escobar and Tuason, 1980;Wagner et al, 1998;Versiani et al, 1999].…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues

Sánchez-Lacay¹,

Lewis‐Fernández²,

Goetz³

et al. 2001

Depress. Anxiety

View full text Add to dashboard Cite

The efficacy and tolerability of nefazodone in the treatment of major depression among Spanish-monolingual Hispanics was examined and compared to historical controls among English-speaking, predominantly non-Hispanic subjects. Fifty monolingual Hispanic outpatients with major depression and a HAM-D17 score > or = 18 were treated with nefazodone in a flexible-dose 8-week open-label protocol. Sixty-three percent of the intent-to-treat (ITT) sample with > or = 1 efficacy visit were considered responders according to CGI-I criteria, falling within the range of response rates (58-69%) reported in six prior nefazodone trials with non-Hispanic subjects. Significant improvement was found for the ITT and completer samples in HAM-D17, HAM-D28, and SCL-90 scores and in two measures of psychosocial functioning. Endpoint mean dose in the ITT sample was 379 mg/day (SD = 170), also within the range of previous trials (321-472 mg/day). Adverse effects were not elevated, with only dry mouth (8%) reported by > 6% of subjects. However, 42% of the sample dropped out of treatment before study termination, usually because of side effects or due to family or work difficulties, a higher rate than previously reported for nefazodone (21-33%). This open trial finds nefazodone to be an efficacious treatment for major depression among monolingual Hispanics, with comparable efficacy to previous controlled trials among non-Hispanic subjects. Double-blind studies are required to confirm this comparable efficacy. Mean endpoint doses and adverse effect rates similar to previous trials do not support the need for reduced doses of nefazodone among Hispanics. However, an elevated rate of treatment discontinuation threatens treatment efficacy among this population. Causes for this elevated rate require explanation, given the apparently unremarkable pattern of adverse effect reports.

show abstract

Section: Discussionsupporting

confidence: 90%

“…These observations from a naturalistic setting have not been confirmed by prospective medication trials among Latin Americans and U.S. Hispanics with imipramine [Escobar and Tuason, 1980], amitriptyline [Versiani et al, 1999], or fluoxetine [Wagner et al, 1998]. …”

Section: Introductionmentioning

confidence: 97%

Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues

Sánchez-Lacay¹,

Lewis‐Fernández²,

Goetz³

et al. 2001

Depress. Anxiety

View full text Add to dashboard Cite

show abstract

“…A possible explanation for the decreased efficacy of the serotonin reuptake inhibitors (SSRI) compared to tricyclic antidpressants such as amitryptilline could reflect the absence of noradrenergic activity of SSRI's (41). In concordance with findings that tricyclic antidepressants as typified by amtriptyline, act to non-selectively inhibit the reuptake of serotonin (5-HT) and noradrenaline (NA) that was found to be helpfull in alleviating the pain symptoms of our and other study samples (8,19).…”

Section: Discussionsupporting

confidence: 87%

“…A number of pharmacological treatments have been studied with varying degrees of success including anticonvulsants, antispasticity agents, anxiolytics, sedatives, antidepressant, antipsychotics and opioids (7)(8)(9). Antidepressants have an antinociceptive effect on various forms of pain but none of the antidepressant drugs, have yet been approved by the FDA for the treatment of FM (10)(11)(12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Konuk

Ortancil

Bostanci

et al. 2010

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychophar

View full text Add to dashboard Cite

“…Gli effetti collaterali e le reazioni avverse sono state meno frequenti e meno gravi nei soggetti trattati con fluoxetina [95].…”

Section: A Disturbo Misto Ansia-depressioneunclassified

Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Pepa

Eandi

2003

View full text Add to dashboard Cite

Fluoxetine has been the first antidepressive agent of the class of selective serotonine reuptake inhibitors (SSRI) to be introduced in therapy, back in 1987. The availability of SSRIs has meant a great advance in the treatment of major depression and other neuro-psychiatric pathologies. In this paper we review the scientific and clinical research on fluoxetine that has been published in the last six years, as the prior work has been extensively examined in a review conducted on the tenth anniversary of its introduction on the market. The review focuses on cost minimization strategies that can be conducted following the introduction of low cost generic fluoxetine.

show abstract

Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison

Cited by 33 publications

References 0 publications

Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues

Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues

A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Contact Info

Product

Resources

About